MADRIGAL PHARMACEUTICALS, INC. - Quarter Report: 2007 June (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2007

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-33277

SYNTA PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware		04-3508648
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)
45 Hartwell Avenue
Lexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 274-8200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act. Check one:

Large accelerated filer o

Accelerated filer o

Non-accelerated filer x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of August 3, 2007, the registrant had 33,832,198 shares of common stock outstanding.

SYNTA PHARMACEUTICALS CORP.

INDEX TO FORM 10-Q

		Page
	PART I FINANCIAL INFORMATION
Item 1.	Financial Statements		3
	Consolidated Balance Sheets as of June 30, 2007 and December 31, 2006 (unaudited)		3
	Consolidated Statements of Operations for the three months and six months ended June 30, 2007 and 2006 (unaudited)		4
	Consolidated Statements of Cash Flows for the six months ended June 30, 2007 and 2006 (unaudited)		5
	Consolidated Statements of Stockholders’ Equity (Deficit) and Comprehensive Loss for the period from inception (March 10, 2000) through June 30, 2007 (unaudited)		6
	Notes to Consolidated Financial Statements (unaudited)		9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		31
Item 4T.	Controls and Procedures		32
	PART II OTHER INFORMATION
Item 1.	Legal Proceedings		33
Item 1A.	Risk Factors		33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		33
Item 3.	Defaults Upon Senior Securities		33
Item 4.	Submission of Matters to a Vote of Security Holders		33
Item 5.	Other Information		33
Item 6.	Exhibits		33
SIGNATURES			34

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)

Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)

	June 30, 2007			December 31, 2006
Assets
Current assets:
Cash and cash equivalents	$	64,526			$	33,687
Restricted cash	83				540
Marketable securities available-for-sale	—				13,137
Prepaid expenses and other current assets	1,315				263
Total current assets	65,924				47,627
Property and equipment, net	5,589				6,067
Deferred offering costs	—				963
Other assets	87				132
Total assets	$	71,600			$	54,789
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$	1,981			$	2,632
Accrued expenses	9,619				6,127
Capital lease obligations—current	2,440				2,330
Other current liabilities	1,831				—
Deferred revenue	—				457
Total current liabilities	15,871				11,546
Capital lease obligations—long-term	3,268				3,170
Total liabilities	19,139				14,716
Convertible preferred stock, at redemption value:
Series A convertible preferred stock, $0.0001 par value per share. Authorized: no shares at June 30, 2007 and 8,000,000 shares at December 31, 2006; no shares issued and outstanding at June 30, 2007 and 8,000,000 shares issued and outstanding at December 31, 2006	—				41,820
Stockholders’ equity (deficit):
Preferred stock, par value $0.0001 per share. Authorized 5,000,000 shares at June 30, 2007 and no shares at December 31, 2006; no shares issued and outstanding at June 30, 2007 and at December 31, 2006	—				—
Common stock, par value $0.0001 per share. Authorized 100,000,000 shares at June 30, 2007 and 158,000,000 shares at December 31, 2006; 33,832,198 shares issued and outstanding at June 30, 2007 and 22,564,068 shares issued and outstanding at December 31, 2006	3				2
Additional paid-in capital	322,111				234,807
Accumulated other comprehensive income	—				2
Deficit accumulated during the development stage	(269,653		)		(236,558		)
Total stockholders’ equity (deficit)	52,461				(1,747		)
Total liabilities and stockholders’ equity (deficit)	$	71,600			$	54,789

See accompanying notes to unaudited consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(Unaudited)

	Three months ended June 30,						Six months ended June 30,						Period from inception (March 10, 2000) through June 30,
	2007			2006			2007			2006			2007
Research grant revenue	$	—		$	—		$	—		$	—			$	1,477
Operating expenses:
Research and development	13,613			13,056			27,158			27,453				207,604
In-process research and development	—			—			—			—				19,671
General and administrative	3,853			1,926			7,321			4,117				41,663
Other compensation expense(1)	—			—			—			—				9,315
Total operating expenses	17,466			14,982			34,479			31,570				278,253
Loss from operations	(17,466		)	(14,982		)	(34,479		)	(31,570		)		(276,776		)
Other income:
Investment income, net	725			336			1,384			713				7,123
Net loss	(16,741		)	(14,646		)	(33,095		)	(30,857		)		(269,653		)
Convertible preferred stock beneficial conversion charge	—			—			58,585			—				58,585
Convertible preferred stock dividends	—			245			—			245				1,859
Net loss attributable to common stockholders	$	(16,741	)	$	(14,891	)	$	(91,680	)	$	(31,102	)		$	(330,097	)
Basic and diluted weighted average common shares outstanding	33,390,082			22,224,734			30,958,130			22,222,604
Basic and diluted net loss attributable to common stockholders per share	$	(0.50	)	$	(0.67	)	$	(2.96	)	$	(1.40	)

(1) Excluded from general and administrative expense.

See accompanying notes to unaudited consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)

Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)

	Six months ended June 30,						Period from inception (March 10, 2000) through June 30,
	2007			2006			2007
Cash flows from operating activities:
Net loss	$	(33,095	)	$	(30,857	)		$	(269,653	)
Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development	—			—				19,671
Common stock issued for licenses	—			—				1,242
Expense deferred offering costs	—			—				1,085
Other stock-related compensation expense	2,907			2,327				24,314
Depreciation and amortization	1,646			1,921				10,603
Changes in operating assets and liabilities, net of acquisitions:
Restricted cash	457			—				(83		)
Prepaid expenses and other current assets	(1,052		)	(1,356		)		(1,055		)
Other assets	45			4				(19		)
Accounts payable	(651		)	(1,523		)		1,401
Accrued expenses	4,455			(608		)		7,744
Deferred revenue	(457		)	—				—
Net cash used in operating activities	(25,745		)	(30,092		)		(204,750		)
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	—			—				(5,586		)
Advances issued to related parties	—			—				(1,630		)
Purchases of marketable securities	(15,014		)	(34,313		)		(490,210		)
Sales and maturities of marketable securities	28,149			72,602				490,210
Repayment of advances from related parties	—			—				1,630
Purchases of property and equipment	(824		)	(642		)		(9,898		)
Net cash provided by (used in) investing activities	12,311			37,647				(15,484		)
Cash flows from financing activities:
Proceeds from issuances of common stock and exercise of common stock warrants, net	44,660			—				240,550
Proceeds from issuance of convertible preferred stock, net	—			39,950				39,961
Proceeds from exercise of stock options	39			2				817
Repurchase of common stock from officers	(290		)	—				(290		)
Proceeds from sale-leaseback of property and equipment	1,154			897				8,628
Payment of capital lease obligation	(1,290		)	(990		)		(4,719		)
Payment of deferred offering costs	—			—				(187		)
Net cash provided by financing activities	44,273			39,859				284,760
Net increase in cash and cash equivalents	30,839			47,414				64,526
Cash and cash equivalents at beginning of period	33,687			23,809				—
Cash and cash equivalents at end of period	$	64,526		$	71,223			$	64,526
Supplemental disclosure of noncash investing and financing activities:
Purchase of equipment under capital lease	$	1,154		$	897			$	9,993
Convertible preferred stock beneficial conversion charge	58,585			—				58,585
Convertible preferred stock dividends	—			245				1,859
Conversion of preferred stock	41,820			—				41,820
Cash paid for interest	265			291				1,132

See accompanying notes to unaudited consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)

Consolidated Statements of Stockholders’ Equity (Deficit) and Comprehensive Loss
(in thousands, except share amounts)
(unaudited)

																				Deficit
																	Accumulated			accumulated
						Additional							Stock				other			during the				Total
	Common stock					paid-in			Deferred				subscription				comprehensive			development				stockholders’				Comprehensive
	Shares		Amount			capital			compensation				receivable				income (loss)			stage				equity (deficit)				loss
Balance at inception		—		$	—		$	—		$	—			$	—			$	—		$	—			$	—			$
Net loss		—		—			—			—				—				—			(78		)		(78		)		(78		)
Balance at December 31, 2000		—		—			—			—				—				—			(78		)		(78		)		$	(78	)
Issuance of common shares to founders		5,100,000		1			1			—				—				—			—				2
Issuance of common shares		1,700,000		—			3,400			—				(225		)		—			—				3,175
Issuance and remeasurement of stock options for services		—		—			120			(120		)		—				—			—				—
Compensation expense related to stock options for services		—		—			—			26				—				—			—				26
Net loss		—		—			—			—				—				—			(381		)		(381		)		(381		)
Balance at December 31, 2001		6,800,000		1			3,521			(94		)		(225		)		—			(459		)		2,744				$	(381	)
Issuance of common shares		3,563,059		—			38,635			—				—				—			—				38,635
Issuance of common stock and warrants for Principia		1,234,875		—			15,860			—				—				—			—				15,860
Proceeds from stock subscription		—		—			—			—				225				—			—				225
Issuance of common stock for licenses		96,111		—			1,042			—				—				—			—				1,042
Issuance of common stock for Diagon		786,463		—			8,525			—				—				—			—				8,525
Issuance and remeasurement of stock options for services		—		—			851			(851		)		—				—			—				—
Compensation expense related to stock options for services		—		—			—			274				—				—			—				274
Net loss		—		—			—			—				—				—			(36,154		)		(36,154		)		(36,154		)
Balance at December 31, 2002		12,480,508		1			68,434			(671		)		—				—			(36,613		)		31,151				$	(36,154	)
Issuance of common shares, net		5,116,790		1			70,479			—				—				—			—				70,480
Amount due from stock subscription		—		—			500			—				(500		)		—			—				—
Issuance of common stock for licenses		18,444		—			200			—				—				—			—				200
Exercise of stock warrants		143,869		—			288			—				—				—			—				288
Exercise of stock options		39,062		—			423			—				—				—			—				423
Modification of employee stock options		—		—			1,289			—				—				—			—				1,289
Issuance and remeasurement of stock options for services		—		—			2,541			(2,541		)		—				—			—				—
Compensation expense related to stock options for services		—		—			—			905				—				—			—				905
Unrealized gain on marketable securities		—		—			—			—				—				33			—				33				33
Net loss		—		—			—			—				—				—			(27,878		)		(27,878		)		(27,878		)
Balance at December 31, 2003		17,798,673		2			144,154			(2,307		)		(500		)		33			(64,491		)		76,891				$	(27,845	)

See accompanying notes to consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)

Consolidated Statements of Stockholders’ Equity (Deficit) and Comprehensive Loss (Continued)
(in thousands, except share amounts)
(unaudited)

																					Deficit
																	Accumulated				accumulated
						Additional								Stock			other				during the				Total
	Common stock					paid-in				Deferred				subscription			comprehensive				development				stockholders’				Comprehensive
	Shares		Amount			capital				compensation				receivable			income (loss)				stage				equity (deficit)				loss
Issuance of common shares under stock subscription	187,500			$	—		$	2,493			$	—			$	500		$	—			$	—			$	2,993			$
Issuance of common shares, net	3,999,996			—			79,900				—				—			—				—				79,900
Issuance of common stock in connection with acquisition	138,336			—			2,213				—				—			—				—				2,213
Issuance of restricted common shares	365,000			—			8,030				(8,030		)		—			—				—				—
Issuance of stock options at less than fair value	—			—			471				(471		)		—			—				—				—
Exercise of stock options	32,421			—			352				—				—			—				—				352
Exercise of stock warrants	28,773			—			58				—				—			—				—				58
Issuance and remeasurement of stock options for services	—			—			1,259				(1,259		)		—			—				—				—
Compensation expense related to stock options for services	—			—			—				1,331				—			—				—				1,331
Compensation expense related to issuance of stock options and restricted stock below fair value	—			—			—				301				—			—				—				301
Unrealized loss on marketable securities	—			—			—				—				—			(149		)		—				(149		)		(149		)
Net loss	—			—			—				—				—			—				(45,934		)		(45,934		)		(45,934		)
Balance at December 31, 2004	22,550,699			2			238,930				(10,435		)		—			(116		)		(110,425		)		117,956				$	(46,083	)
Issuance of restricted common shares	96,589			—			1,425				(1,425		)		—			—				—				—
Forfeitures of restricted common shares	(40,000	)		—			(881		)		743				—			—				—				(138		)
Exercise of stock warrants	67,138			—			134				—				—			—				—				134
Issuance of stock options for services	—			—			201				(201		)		—			—				—				—
Forfeitures of stock options for services	—			—			(329		)		329				—			—				—				—
Remeasurement of stock options for services	—			—			(451		)		451				—			—				—				—
Compensation expense related to stock options for services	—			—			—				1,142				—			—				—				1,142
Compensation expense related to issuance of stock options and restricted stock below fair value	—			—			—				2,171				—			—				—				2,171
Unrealized gains on marketable securities	—			—			—				—				—			75				—				75				75
Net loss	—			—			—				—				—			—				(68,863		)		(68,863		)		(68,863		)
Balance at December 31, 2005	22,674,426			$	2		$	239,029			$	(7,225	)		$	—		$	(41	)		$	(179,288	)		$	52,477			$	(68,788	)
Eliminate deferred stock compensation	—			—			(7,225		)		7,225				—			—				—				—
Convertible preferred stock dividends	—			—			(1,859		)		—				—			—				—				(1,859		)
Forfeitures of restricted common shares	(127,500	)		—			—				—				—			—				—				—
Issuance of common shares for services	4,875			—			69				—				—			—				—				69
Issuance of restricted common shares	12,142			—			—				—				—			—				—				—
Exercise of stock options	125			—			2				—				—			—				—				2
Compensation expense related to stock options for services	—			—			4,791				—				—			—				—				4,791
Unrealized gains on marketable securities	—			—			—				—				—			43				—				43				43
Net loss	—			—			—				—				—			—				(57,270		)		(57,270		)		(57,270		)
Balance at December 31, 2006	22,564,068			$	2		$	234,807			$	—			$	—		$	2			$	(236,558	)		$	(1,747	)		$	(57,227	)

See accompanying notes to consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development Stage Company)

Consolidated Statement of Stockholders’ Equity (Deficit) and Comprehensive Loss (Continued)

(in thousands, except share amounts)

(unaudited)

														Deficit
										Accumulated				accumulated
						Additional				other				during the				Total
	Common stock					paid-in				comprehensive				development				stockholders’				Comprehensive
	Shares		Amount			capital				income (loss)				stage				equity (deficit)				loss
Issuance of common shares in IPO, net	5,000,000			—			44,660				—				—				44,660
Conversion of convertible preferred stock	6,278,765			1			41,819				—				—				41,820
Issuance of restricted common shares	15,661			—			—				—				—				—
Repurchase of previously restricted common shares	(29,046	)		—			(290		)		—				—				(290		)
Exercise stock options	2,750			—			39				—				—				39
Compensation expense related to stock options for services	—			—			2,907				—				—				2,907
Reclassification of vested stock options granted to non-employee consultants to liabilities	—			—			(1,831		)		—				—				(1,831		)
Unrealized gains on marketable securities	—			—			—				(2		)		—				(2		)		(2		)
Net loss	—			—			—				—				(33,095		)		(33,095		)		(33,095		)
Balance at June 30, 2007	33,832,198			$	3		$	322,111			$	—			$	(269,653	)		$	52,461			$	(33,097	)

See accompanying notes to unaudited consolidated financial statements.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements

(1) Nature of Business

Synta Pharmaceuticals Corp. (the “Company”) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs that address severe medical conditions, including cancer and chronic inflammatory diseases.

The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with FDA and other government regulations.

(2) Summary of Significant Accounting Policies

Basis of Presentation

Since its inception, the Company has devoted its efforts to research, product development, and securing financing and has not earned significant revenue from its planned principal operations. Accordingly, the consolidated financial statements are presented in accordance with Statement of Financial Accounting Standards (SFAS) No. 7, Accounting and Reporting by Development-Stage Enterprises.

The accompanying interim balance sheet as of June 30, 2007, the consolidated statements of operations and cash flows for the three months and six months ended June 30, 2007 and 2006 and the period from inception (March 10, 2000) through June 30, 2007, and the statement of stockholders’ equity (deficit) for the period from inception (March 10, 2000) through June 30, 2007 are unaudited. The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2006.

In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting solely of normal recurring adjustments and accruals necessary for the fair presentation of the Company’s financial position at June 30, 2007 and its results of operations and cash flows for the three months and six months ended June 30, 2007 and 2006 and the period from inception (March 10, 2000) through June 30, 2007. The results for the three months and six months ended June 30, 2007 are not necessarily indicative of results to be expected for the year ending December 31, 2007 or subsequent interim periods.

The accounting policies underlying these interim financial statements are set forth in the consolidated financial statements for the year ended December 31, 2006.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(2) Summary of Significant Accounting Policies (Continued)

Principles of Consolidation

The consolidated financial statements include the financial statements of Synta Pharmaceuticals Corp. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include long-term contract accruals, recoverability of long-lived and deferred tax assets, valuation of acquired in-process research and development, measurement of stock-based compensation, and the fair value of the Company's common stock. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Stock-Based Compensation

Effective January 1, 2006, the Company adopted SFAS No. 123(R), Share-Based Payment (SFAS No. 123(R)) using the modified prospective method of transition for employee stock option awards granted after January 17, 2005 (valued using the fair value method), and using the prospective method for awards granted prior to January 17, 2005 (valued using the minimum value method). Therefore, compensation cost recognized in the three months and six months ended June 30, 2007 and 2006 includes: (a) compensation costs related to the vesting of employee stock options granted after January 17, 2005 but prior to January 1, 2006, based on the grant date fair value method estimated in accordance with the provisions of SFAS No. 123, Accounting for Stock-Based Compensation (SFAS No. 123) adjusted for estimated forfeitures, (b) compensation costs related to the continued vesting of nonvested restricted stock awards granted prior to January 1, 2006, and (c) compensation costs for all share-based payments granted or modified subsequent to January 1, 2006, based on the provisions of SFAS No. 123(R).

The Company uses the Black-Scholes option pricing model as the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. Since the Company has a limited history of stock activity, expected volatility is based on historical data from several public companies similar in size and value to the Company. The Company will continue to use a weighted average approach using historical volatility and other similar public entity volatility information until historical volatility of the Company is relevant to measure expected volatility for future option grants. The Company estimates the forfeiture rate based on historical data. Based on an analysis of historical forfeitures, the Company has applied a forfeiture rate of 10% to all options vesting in the three months and six months ended June 30, 2007 and 2006. The analysis will be re-evaluated at least annually and the forfeiture rate will be adjusted as necessary. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected lives for options granted represents the period of time that options

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(2) Summary of Significant Accounting Policies (Continued)

granted are expected to be outstanding. Since January 1, 2006 the Company has used the simplified method for determining the expected lives of options.

For the three months and six months ended June 30, 2007 and 2006, the fair value of each employee stock option award was estimated on the date of grant based on the fair value method using the Black-Scholes option pricing valuation model with the following weighted average assumptions:

									Period from
									inception
									(March 10,
	Three months				Six months				2000)
	ended				ended				through
	June 30,				June 30,				June 30,
	2007		2006		2007		2006		2007
Risk-free interest rate	4.67	%	5.03	%	4.65	%	4.62	%		3.81	%
Expected life in years	6.25		6.25		6.25		6.25			5.42
Volatility	75	%	75	%	75	%	75	%		35	%
Expected dividend yield	—		—		—		—			—
Weighted average grant-date fair value	$5.93		$9.86		$6.22		$9.80			$5.48

For awards with graded vesting, the Company allocates compensation costs under SFAS No. 123(R) on a straight-line basis over the requisite service period. The Company amortized the fair value of each option over each option's service period, which is generally the vesting period.

The Company accounts for stock options issued to non-employees in accordance with the provisions of SFAS No. 123 and Emerging Issues Task Force (EITF) No. 96-18, Accounting for Equity Instruments that are Issued to Other than Employees, or in Conjunction with Selling Goods or Services, which requires valuing and remeasuring such stock options to the current fair value until the performance date has been reached.

Certain of the Company’s options granted to non-employees that are fully vested and no longer subject to a performance requirement are subject to EITF Issue No. 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, which requires the stock options held by certain non-employee consultants to be accounted for as liability awards. The fair value of these vested and unexercised awards was recognized as liability awards starting in April 2007 following the registration of stock options under Form S-8, using the Black-Scholes model. As of June 30, 2007, a liability of $1,831,000 was reflected in the balance sheet as other current liabilities. The fair value of the award is re-measured at each financial statement reporting date until the options are exercised or expire. When and if non-employee consultants exercise their Company options or the Company options expire, the corresponding liability will be reclassified to equity. As of June 30, 2007, vested stock options to acquire 339,442 shares of common stock held by non-employee consultants remained unexercised.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(2) Summary of Significant Accounting Policies (Continued)

The following table outlines the details of recognized and unrecognized expense for these stock-based compensation arrangements (in thousands):

	Stock				Stock
	compensation				compensation
	expense for the				expense for the				Unrecognized stock
	three months ended				six months ended				compensation
	June 30,				June 30,				expense as of
	2007		2006		2007		2006		June 30, 2007
Employee stock options	$	1,024	$	761	$	1,946	$	1,333		$	11,660
Repriced employee stock options	34		43		69		327			227
Employee options issued below fair value	2		28		4		56			25
Non-employee stock options	13		59		44		155			139
Restricted stock	422		412		844		456			3,839
	$	1,495	$	1,303	$	2,907	$	2,327		$	15,890

There was no income tax benefit related to the Company’s stock-based compensation arrangements for employees and non-employee awards and unrecognized stock-based compensation expense will be recognized over a weighted average period of 4.5 years.

Stock-based compensation expense is allocated as follows (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2007		2006		2007		2006
Research and development	$	1,117	$	978	$	2,168	$	1,676
General and administrative	378		325		739		651
Total	$	1,495	$	1,303	$	2,907	$	2,327

Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (ISOs). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company will receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a qualifying disposition occurs. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for the share-based compensation arrangement due to the fact that the Company does not believe it is more likely than not it will recognize any deferred tax assets from such compensation cost recognized in the current period.

Basic and Diluted Net Loss Per Common Share

Net loss per share is computed based on the guidance of SFAS No. 128, Earnings Per Share (SFAS 128), requiring companies to report both basic net loss per common share, which is computed using the weighted average number of common shares outstanding during the period, and diluted net loss per common share, which is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(2) Summary of Significant Accounting Policies (Continued)

However, for all periods presented, diluted net loss per common share is the same as basic net loss per common share as the inclusion of weighted average shares of common stock issuable upon the exercise of stock options and warrants and conversion of convertible preferred stock would be anti-dilutive.

The following table summarizes securities outstanding at each of the periods presented which were not included in the calculation of diluted net loss per share since their inclusion would be anti-dilutive.

	June 30,
	2007	2006
Common stock options	3,912,450	3,176,185
Unvested restricted stock	170,661	285,000

Recent Accounting Pronouncements

In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FAS 109 (Interpretation No. 48). This interpretation clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with FASB Statement No. 109, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken in a tax return. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Interpretation No. 48 is effective for fiscal years beginning after December 15, 2006. Earlier application is encouraged if the company has not yet issued financial statements, including interim financial statements, in the period Interpretation No. 48 is adopted. The Company adopted this Interpretation No. 48 effective January 1, 2007 and its adoption had no impact on its consolidated results of operations and financial position.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157), which provides guidance for using fair value to measure assets and liabilities. The pronouncement clarifies (1) the extent to which companies measure assets and liabilities at fair value; (2) the information used to measure fair value; and (3) the effect that fair value measurements have on earnings. SFAS No. 157 will apply whenever another standard requires (or permits) assets or liabilities to be measured at fair value. SFAS No. 157 will be applicable to us as of January 1, 2008. The Company does not believe the adoption of SFAS No. 157 will have a material impact on its overall financial position or results of operations.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS No. 159) including an amendment of SFAS No. 115, which permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 is effective for the Company beginning in fiscal 2008. The Company is currently evaluating SFAS No. 159 and the impact that it may have on its results of operations or financial position.

In June 2007, the EITF issued EITF No. 07-03, Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, (EITF 7-03), which provides guidance for upfront payments related to goods and services of research and development costs. EITF 07-03 is effective for fiscal years beginning after December 15, 2007. The Company is currently evaluating EITF 7-03 and the impact that it may have on its results of operations or financial position.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(3) Cash, Cash Equivalents and Marketable Securities

A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of June 30, 2007 and December 31, 2006 is as follows:

	June 30, 2007
	Cost		Unrealized gains			Unrealized losses			Fair value
	(in thousands)
Cash and cash equivalents:
Cash and money market funds	$	64,526		$	—		$	—	$	64,526
Marketable securities:
Corporate bonds:
Due within 1 year	—			—			—		—
Total cash and cash equivalents and marketable securities	$	64,526		$	—		$	—	$	64,526

	December 31, 2006
	Cost		Unrealized gains			Unrealized losses			Fair value
	(in thousands)
Cash and cash equivalents:
Cash and money market funds	$	33,687		$	—		$	—	$	33,687
Marketable securities:
Corporate bonds:
Due within 1 year	13,135			2			—		13,137
Total cash and cash equivalents and marketable securities	$	46,822		$	2		$	—	$	46,824

(4) Property and Equipment

Property and equipment consist of the following:

	June 30, 2007				December 31, 2006
	(in thousands)
Laboratory equipment		$	9,644			$	8,724
Leasehold improvements		3,962				3,854
Computers and software		1,075				1,042
Furniture and fixtures		727				677
		15,408				14,297
Less accumulated depreciation and amortization		(9,819		)		(8,230		)
		$	5,589			$	6,067

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(4) Property and Equipment (Continued)

Depreciation and amortization expenses of property and equipment were approximately $1,646,000, $1,921,000 and $10,603,000 for the six months ended June 30, 2007 and 2006 and the period from inception (March 10, 2000) through June 30, 2007, respectively.

(5) Stockholders’ Equity

Common Stock

Reverse Stock Split

In January 2007, the Board of Directors and the stockholders of the Company approved (i) a 1-for-4 reverse stock split, which was effected on February 2, 2007, subject to a reduction for fractional shares that were paid for in cash, (ii) an adjustment of the authorized common shares to 100,000,000, which became effective upon the completion of the initial public offering (“IPO”) of the Company’s common stock, and (iii) an adjustment in the number of common shares reserved under the 2006 Stock Option Plan to 2,500,000. All share data shown in the accompanying consolidated financial statements has been retroactively restated to reflect the reverse split. The reverse stock split did not alter the par value of the common stock, which is $0.0001 per share, or modify any voting rights or other terms of the common stock.

Initial Public Offering

In February 2007, the Company raised $50.0 million in gross proceeds from the sale of 5,000,000 shares of its common stock in the IPO at $10.00 per share. The net offering proceeds after deducting approximately $5.3 million in expenses for underwriters’ discounts, fees and commissions, legal, accounting, printing, listing and filing fees, and miscellaneous expenses were approximately $44.7 million. As of December 31, 2006, the Company had approximately $1.0 million in deferred IPO costs related to this offering. All outstanding shares of the Company’s Series A convertible preferred stock and $1.9 million in accumulated dividends on the Series A convertible preferred stock were converted into 6,278,765 shares of common stock upon the completion of the IPO.

In accordance with EITF, No. 98-5, Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios, and EITF, No. 00-27, Application of Issue No. 98-5 to Certain Convertible Instruments, the Company recorded a non-cash beneficial conversion charge of approximately $58.6 million in February 2007 in connection with the contingent adjustable conversion feature of the Series A convertible preferred stock.

(6) Stock Option Plans

In March 2006, the Company terminated the Synta Pharmaceuticals Corp. 2001 Stock Plan (the 2001 Stock Option Plan) and adopted the Synta Pharmaceuticals Corp. 2006 Stock Plan (the 2006 Stock Option Plan). The 2006 Stock Option Plan provides for the grant of incentive stock options, nonstatutory stock options and restricted stock to employees, officers, directors and consultants to the Company. A total of 2,500,000 shares of common stock have been reserved for issuance under the 2006 Stock Option Plan. The administration of the 2006 Stock Option Plan is under the general supervision of the board of directors. The exercise price of the stock options is determined by the board of directors or a committee

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(6) Stock Option Plans (Continued)

thereof, provided that incentive stock options are granted at not less than fair market value of the common stock on the date of grant and expire no later than ten years from the date the option is granted.

As of June 30, 2007, the Company had options outstanding to purchase 2,854,505 shares of its common stock, had outstanding 155,000 restricted shares of common stock and had no shares available for future issuance under the 2001 Stock Option Plan.

As of June 30, 2007, the Company had options outstanding to purchase 982,945 shares of its common stock, had outstanding 15,661 restricted shares of common stock and had available 1,489,252 shares available for future issuance under the 2006 Stock Option Plan.

As of June 30, 2007, the Company had options outstanding to purchase 75,000 shares of its common stock that were granted outside of the 2001 Stock Plan and 2006 Stock Plan.

General Option Information

The following table summarizes stock option activity during the six months ended June 30, 2007:

	Shares available for Grant		Options		Weighted average exercise price of options under plan
Outstanding at January 1, 2007	2,326,358		3,044,343			$	11.90
Granted	(974,809	)	959,148			8.98
Exercised	—		(2,750	)		14.00
Cancelled(1)	43,953		(88,291	)		11.21
Additional shares reserved(2)	93,750		—			—
Outstanding at June 30, 2007	1,489,252		3,912,450			$	11.19
Exercisable at June 30, 2007			2,341,576			$	11.27

(1) In March 2006, the Company terminated the 2001 Stock Option Plan and adopted the 2006 Stock Option Plan. Options granted under the 2001 Stock Option Plan and cancelled subsequent to the March 2006 termination of the 2001 Stock Option Plan do not return to the pool of options available for future issuance.

(2) In January 2007, the Company authorized the increase in shares reserved for future issuance from 2,406,250 to 2,500,000.

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(6) Stock Option Plans (Continued)

Included in the Company’s stock options outstanding at June 30, 2007 are 368,430 options issued to non-employee consultants with a weighted average exercise price of $8.45 of which 339,442 are vested. The weighted average period over which $139,000 of unrecognized compensation expense is expected to be recognized is 3.3 years. The following table summarizes information about outstanding and exercisable stock options at June 30, 2007:

	Options Outstanding									Options Exercisable
			Weighted		Weighted						Weighted		Weighted
			average		average						average		average
			remaining		exercise			Aggregate			remaining		exercise			Aggregate
	Number		contractual		price			intrinsic		Number	contractual		price			intrinsic
Exercise price	outstanding		life (years)		per share			value		exercisable	life		per share			value
$2.00		164,762		4.41		$	2.00	$	1,038,001	164,762		4.41		$	2.00	$	1,038,001
8.15-8.75		712,458		9.68		8.70		—		—		—		—		—
10.00-10.84		1,603,843		6.10		10.74		—		1,399,543		5.60		10.84		—
14.00		1,431,387		7.90		14.00		—		777,271		7.55		14.00		—
		3,912,450		7.34		$	11.19	$	1,038,001	2,341,576		6.16		$	11.27	$	1,038,001

Non-Vested (“Restricted”) Stock Awards With Service Conditions

The Company’s share-based compensation plan provides for awards of restricted shares of common stock to officers, other employees and non-employee directors. Restricted stock awards are subject to forfeiture if employment terminates during the prescribed retention period. The remaining unrecognized compensation expense on restricted stock at June 30, 2007 was $3,839,000. The weighted average period over which the balance is expected to be recognized is 1.6 years. Vesting may accelerate upon the U.S. Food and Drug Administration’s approval of the Company’s first New Drug Application.

General Restricted Shares Information

The following table summarizes restricted stock activity during the six months ended June 30, 2007:

	Shares		Weighted average grant date fair value
Outstanding at January 1, 2007	291,073			$	21.15
Granted	15,661			$	8.30
Vested	(136,073	)		$	21.64
Cancelled	—			—
Outstanding at June 30, 2007	170,661			$	19.57

SYNTA PHARMACEUTICALS CORP.
(A Development-Stage Company)
Notes to Unaudited Consolidated Financial Statements (Continued)

(6) Stock Option Plans (Continued)

In January 2007, the Company repurchased 29,046 shares of its previously restricted common stock from certain officers and non-officer employees in order to fund the minimum statutory tax withholding requirements related to the vesting of 80,000 shares of restricted common stock. In June 2007, these treasury shares were retired.

(7) Accrued Expenses

Accrued expenses consist of the following:

	June 30, 2007			December 31, 2006
	(in thousands)
Contracted research costs		$	5,309		$	3,052
Compensation and benefits		1,599			1,196
Professional fees		1,912			1,451
Other		799			428
		$	9,619		$	6,127

(8) Related-Party Transactions

Consulting Agreements and Agreement and Release

The Company paid its scientific founder, who is also a member of its Board of Directors, fees under a consulting agreement and installment payments related to an Agreement and Release. In March 2007, the Company amended the consulting agreement to reduce the fee from $25,000 to $10,000 per month. The Company made payments of approximately $140,000 and $200,000 in the six months ended June 30, 2007 and 2006, respectively, in connection with these agreements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read this discussion together with the consolidated financial statements, related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. The following discussion may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. These risks could cause our actual results to differ materially from any future performance suggested below.

Overview

We are a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with large potential markets, including cancer and chronic inflammatory diseases. We have two drug candidates in clinical trials, two drug candidates in preclinical studies, and one program undergoing lead optimization. In September 2006, we announced positive results for our most advanced drug candidate, STA-4783, in a Phase 2b clinical trial in patients with metastatic melanoma. Based on these positive results, we intend to initiate a pivotal Phase 3 clinical

trial in metastatic melanoma in the third quarter of 2007. In addition, we expect to announce by the end of 2007 plans for initiating clinical trials of STA-4783 in additional cancer types. For our second clinical-stage drug candidate, apilimod, we are currently conducting a Phase 2a clinical trial in patients with rheumatoid arthritis and sponsoring a Phase 2a clinical trial in patients with common variable immunodeficiency, or CVID. Our two next most advanced drug candidates, STA-9090 and STA-9584, are currently in preclinical development, and we expect to file an investigational new drug application, or IND, for STA-9090 in the third quarter of 2007. Our CRAC ion channel inhibitor program is currently in the lead optimization stage. All of our drug candidates were discovered and developed internally, using our unique chemical compound library, and the chemistry, biology, and pharmaceutical development assets and capabilities built over the combined history of Synta and its predecessor companies. We have retained all rights to all of our drug candidates and programs across all geographic markets and therapeutic indications.

We were incorporated in March 2000 and commenced operations in July 2001. Since that time, we have been principally engaged in raising capital and in the discovery and development of novel drug candidates. In September 2002, we acquired all of the outstanding stock of Principia Associates, Inc., an operating biopharmaceutical company and a related party, in exchange for our common stock, common stock warrants and forgiveness of notes receivable with an aggregate value of $16.9 million. In July 2002, Principia had acquired all of the outstanding stock of SBR Pharmaceuticals Corp. (formerly Shionogi BioResearch Corp.), an operating biopharmaceutical company, in exchange for cash of $12.5 million. In December 2002, we acquired all of the outstanding stock of Diagon Genetics, Inc., a related party, whose activities consisted of owning the rights to the development of certain intellectual property, in exchange for cash of $5.0 million and $8.5 million of our common stock. In January 2004, we acquired the assets, consisting principally of rights to intellectual property, and assumed certain liabilities of Cancer Genomics, Inc., Kava Pharmaceuticals, Inc. and SinglePixel Biomedical, Inc., collectively referred to herein as CKS, all related parties, in a single transaction in exchange for our common stock with a value of $2.2 million.

Since our inception, we have had no revenues from product sales. We have funded our operations principally with $195.4 million in net proceeds from private placements of our common stock, $40.0 million in net proceeds from a private placement of our Series A convertible preferred stock and $44.7 million in net proceeds from our initial public offering, which, together with the exercise of common stock warrants and options, provided aggregate net cash proceeds of approximately $281.3 million through June 30, 2007.

In February 2007, we raised $50.0 million in gross proceeds from the sale of 5,000,000 shares of our common stock in an initial public offering (“IPO”) at $10.00 per share. The net offering proceeds to us after deducting approximately $5.3 million in expenses for underwriters’ discounts, fees and commissions,

legal, accounting, printing, listing and filing fees, and miscellaneous expenses were approximately $44.7 million. All outstanding shares of the Series A convertible preferred stock and $1.9 million in accumulated dividends on the Series A convertible preferred stock were converted into 6,278,765 shares of common stock upon the completion of the IPO. In accordance with Emerging Issues Task Force, or EITF, No. 98-5, Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios, and EITF, No. 00-27, Application of Issue No. 98-5 to Certain Convertible Instruments, we recorded a non-cash beneficial conversion charge of approximately $58.6 million in February 2007 in connection with the contingent adjustable conversion feature of the Series A convertible preferred stock.

We have devoted substantially all of our capital resources to the research and development of our drug candidates and to the acquisitions of Principia and Diagon. We have never been profitable and, as of June 30, 2007, we had an accumulated deficit of $269.7 million. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and begin operating as a public company. We will need to generate significant revenues to achieve profitability and may never do so.

Financial Operations Overview

Revenue

We have not yet generated any product revenue and do not expect to generate any product revenue for the foreseeable future. We have recognized, in the aggregate, $1.5 million of revenue since our inception. This revenue was derived entirely from government research grants. We will seek to generate revenue from product sales, and possibly from collaborative or strategic relationships, which could include research and development, profit sharing, and milestone payments, as well as royalties. In the future, we expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing and amount of payments received under any future collaborative or strategic relationships, and the amount and timing of payments we receive upon the sale of our drug candidates, to the extent any is successfully commercialized.

Research and Development

Research and development expense consists of costs incurred in connection with developing and advancing our drug discovery technology and identifying and developing our drug candidates. From inception through June 30, 2007, we incurred research and development expense in the aggregate of $207.6 million. We charge all research and development expenses to operations as incurred.

Our research and development expense consists of:

· internal costs associated with research, preclinical and clinical activities;

· payments to third party contract research organizations, investigative sites and consultants in connection with our preclinical and clinical development programs;

· costs associated with drug formulation and supply of drugs for clinical trials;

· personnel related expenses, including salaries, stock-based compensation, benefits and travel; and

· overhead expenses, including rent and maintenance of our facilities, and laboratory and other supplies.

For the periods indicated below, research and development expenses for our clinical-stage drug candidates, STA-4783 and apilimod, and our other early-stage and discontinued programs were as follows (in millions):

	Three Months Ended June 30,				Six months Ended June 30,
	2007		2006		2007		2006
STA-4783	$	8.9	$	1.1	$	16.0	$	2.4
Apilimod	0.1		5.0		1.0		13.0
Early-stage and discontinued programs	4.6		7.0		10.2		12.1
Total	$	13.6	$	13.1	$	27.2	$	27.5

We do not know if we will be successful in developing our drug candidates. While expenses associated with the completion of our current clinical programs are expected to be substantial and increase, we believe that accurately projecting total program-specific expenses through commercialization is not possible at this time. The timing and amount of these expenses will depend upon the costs associated with potential future clinical trials of our drug candidates, and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs and product manufacturing costs, many of which cannot be determined with accuracy at this time based on our stage of development. This is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of unanticipated events arising during clinical development, including with respect to:

· the number of clinical sites included in the trial;

· the length of time required to enroll suitable subjects;

· the number of subjects that ultimately participate in the trials; and

· the efficacy and safety results of our clinical trials and the number of additional required clinical trials.

Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals and the expense of filing, prosecuting, defending or enforcing any patent claims or other intellectual property rights. In addition, we may obtain unexpected or unfavorable results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some drug candidates or focus on others. A change in the outcome of any of the foregoing variables in the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in any of our clinical trials, we would be required to expend significant additional financial resources and time on the completion of clinical development. Additionally, future commercial and regulatory factors beyond our control will evolve and therefore impact our clinical development programs and plans over time.

Despite this uncertainty, however, our development strategy for our lead clinical-stage drug candidate, STA-4783, is currently based on a number of assumptions that allow us to make broad estimates of certain clinical trial expenses. We expect to initiate a pivotal Phase 3 clinical trial of STA-4783 in metastatic melanoma in the third quarter of 2007, and we expect the cost to complete this trial, including the cost of clinical supplies of STA-4783, together with the costs of related nonclinical toxicology and other testing to support the trial, will be in the range of $40 to $60 million. To date, we have not entered into any collaboration with a strategic corporate partner for the development of this drug candidate, and unless we do so in the future, we expect to internally finance all clinical development of this candidate. We do not expect to receive regulatory approval of any of our drug candidates until 2009 at the earliest, if at all.

Beyond our two lead drug candidates, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success, as well as commercial potential.

In-Process Research and Development

Our acquisitions of Principia and Diagon in 2002 and the CKS assets in 2004 resulted in in-process research and development charges to our consolidated statements of operations in the respective periods of the acquisitions. The total amount of in-process research and development charges related to these acquisitions was approximately $19.7 million. We used the income approach to estimate the fair value of in-process research and development for the Principia and Diagon acquisitions and the cost approach for the CKS acquisition. Generally, in cases where we acquired assets and assumed liabilities, and where the purchase price exceeded the fair value of net assets acquired, the excess purchase price has been allocated to acquired intangible assets, principally in-process research and development. If the in-process research and development acquired is incomplete and has no alternative future use, we record the value of the in-process research and development as an expense in our consolidated statement of operations in the period of the acquisition.

Under the income approach, each project was analyzed to determine the utilization of core technology; the complexity, cost and time to complete development; any alternative future use or current technological feasibility; and the stage of completion. Future cash flows were estimated, taking into account the expected life cycles of the product and the underlying technology, relevant market sizes and industry trends. The estimated net cash flows from these products were based on management’s estimates of related revenues, cost of goods sold, research and development costs, selling, general and administrative costs, and income taxes. Material cash flows from each of the projects valued under the income approach were assumed to commence in the year following project completion. Discount rates and probability factors were determined based on the nature of the technology, the stage of completion of the projects, the complexity of the development effort and the risks associated with reaching technological feasibility of the projects.

We recorded an in-process research and development charge of $13.9 million as a result of the Principia acquisition, principally comprised of an $8.7 million charge related to STA-4783 and a $3.7 million charge related to apilimod. The discount rates applied in the valuations ranged from 30% to 40%.

Projects acquired in the Diagon acquisition related to ion channel technology and anti-allergy antibody projects and resulted in in-process research and development valuation of approximately $3.0 million and $1.2 million, respectively. The discount rate applied in the valuations was 30%.

The CKS in-process research and development charge of $1.6 million pertained to the technology related to the treatment of anxiety and general pain. The value of the CKS in-process research and development charge was based on the cost approach. During 2004, after an initial investment to advance the technology, we ceased further funding of the project.

We believe each of the acquired technologies for which in-process research and development was recorded was unique and patents were filed for each of the acquired projects. Completion of these projects will be a complex and costly undertaking, involving continuing research, animal studies and human clinical trials.

General and Administrative

General and administrative expense consists primarily of salaries and related expenses for personnel in executive, finance, business development, investor relations, human resources and administrative

functions. Other costs include stock-based compensation costs, legal costs of pursuing patent protection of our intellectual property, fees for general legal, accounting and other professional services, and overhead-related costs not otherwise included in research and development. We anticipate increases in general and administrative expense relating to public-company requirements and initiatives. These increases will likely include legal fees, accounting fees, consulting fees and directors and officers liability insurance premiums, as well as fees for investor relations services.

Convertible Preferred Stock Dividends

Convertible preferred stock dividends consist of cumulative but undeclared dividends that were payable on our Series A convertible preferred stock. The Series A convertible preferred stock accrued dividends at 8% per year. For the year ended December 31, 2006, dividends recorded with respect to the Series A convertible preferred stock totaled $1.9 million. All outstanding shares of Series A convertible preferred stock and the $1.9 million in accumulated dividends were converted into 6,278,765 shares of our common stock upon completion of the IPO in February 2007. There were no dividends recorded with respect to the Series A convertible preferred stock in the six months ended June 30, 2007.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. We are required to make estimates and judgments with respect to accrued expenses, acquisitions and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources and the reported amounts of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following accounting policies and estimates are most critical to aid you in understanding and evaluating our reported financial results.

Accrued Expenses

As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves identifying services which have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for such service as of each balance sheet date in our financial statements. Given our current business, the primary area of uncertainty concerning accruals which could have a material effect on our business is with respect to service fees paid to contract manufacturers in conjunction with the production of clinical drug supplies and to contract research organizations in connection with our preclinical studies and clinical trials. In connection with all of the foregoing service fees, our estimates are most affected by our understanding of the status and timing of services provided. The majority of our service providers, including contract research organizations, invoice us in arrears for services performed. In the event that we do not identify some costs which have begun to be incurred, or we under or over estimate the level of services performed or the costs of such services in a given period, our reported expenses for such period would be too low or too high. We currently reflect the over or under accrual of expenses directly in our operations in the period the amount was determined.

Our arrangements with contract research organizations in connection with clinical trials often provide for payment prior to commencing the project or based upon predetermined milestones throughout the period during which services are expected to be performed. We recognize expense relating to these arrangements based on the various services provided over the estimated time to completion. The date on which services commence, the level of services performed on or before a given date, and the cost of such services are often determined based on subjective judgments. We make these judgments based upon the facts and circumstances known to us based on the terms of the contract or our ongoing monitoring of service performance. In the three months and six months ended June 30, 2007 and 2006, respectively, we had arrangements with multiple contract research organizations whereby these organizations commit to performing services for us over multiple reporting periods. We currently recognize and plan to continue to recognize the expenses associated with these arrangements based on our expectation of the timing of the performance of components under these arrangements by these organizations. Generally, these components consist of the costs of setting up the trial, monitoring the trial, closing the trial and preparing the resulting data.

With respect to financial reporting periods presented in this Quarterly Report on Form 10-Q, and based on our receipt of invoices from our third party providers, the timing of our actual costs incurred have not differed materially from our estimated timing of such costs. In light of the foregoing, we do not believe our estimates of future expenses and our practice of making judgments concerning the accrual of expenses are reasonably likely to change in the future. There were no changes in our estimates and accruals for contract service fees that had a material effect on our net losses in the three months and six months ended June 30, 2007 and 2006, respectively.

Acquisitions

We apply purchase accounting in our acquisitions. Under purchase accounting, we allocate the purchase price to assets acquired and liabilities assumed based upon our analysis and estimates of fair values. Our analysis generally includes three approaches to estimate the value of acquired assets. The cost approach measures the value of an asset by quantifying the aggregate expenditures that would be required to replace the subject asset, given its future service capability. The market approach employs a comparative analysis of actual transactions in which similar assets have been transferred or in which businesses have been sold whose value is comprised largely of assets similar to the subject assets. The income approach is an estimation of the present value of the future monetary benefits expected to flow to the owner of the asset during its remaining useful life. We generally use the income approach to estimate the fair value of in-process research and development. We perform a discounted cash flow analysis, utilizing anticipated revenues, expenses and net cash flow forecasts related to the technology. Given the high risk associated with the development of new drugs, we probability adjust the revenue and expense forecasts to reflect the risk of failing to advance through the clinical development and regulatory approval process based on the stage of development in the regulatory process. Such a valuation requires significant estimates and assumptions. We believe the fair value assigned to the in-process research and development reflected in our consolidated financial statements is based on reasonable assumptions. However, these assumptions may be incomplete or inaccurate, and unanticipated events and circumstances may occur. If the in-process research and development is incomplete and has no alternative future value, we record the full value of the in-process research and development as an expense in the period of the acquisition.

Stock-Based Compensation

Effective January 1, 2006, we adopted Statement of Financial Accounting Standards, Share-Based Payment, or SFAS No. 123R, for stock-based awards to employees, using the modified prospective method of transition for awards granted after January 17, 2005 (valued using the fair value method), and using the prospective method for awards granted prior to January 17, 2005 (valued using the minimum value

method). Therefore, compensation cost recognized in the year ended December 31, 2006 includes: (1) compensation costs related to the vesting of stock options granted after January 17, 2005 but prior to January 1, 2006, based on the grant date fair value method estimated in accordance with the provisions of SFAS 123 adjusted for estimated forfeitures, (2) compensation costs related to the continued vesting of nonvested restricted stock awards granted prior to January 1, 2006, and (3) compensation costs for all share-based payments granted or modified subsequent to January 1, 2006, based on the provisions of SFAS No. 123R.

We continue to use the Black-Scholes option pricing model as the most appropriate valuation method for our option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. Since we do not have a history of stock trading activity, expected volatility is based on historical data from several public companies similar in size and value to us. We will continue to use a weighted average approach using historical volatility and other similar public entity volatility information until historical volatility of our common stock is relevant to measure expected volatility for future option grants. We estimate the forfeiture rate based on historical data. Our options generally vest 25% after one year of service and quarterly over three years thereafter. Based on an analysis of historical forfeitures, we applied a forfeiture rate of 10% to all options that vest upon completion of the first year of service following the date of grant. The analysis will be re-evaluated at least annually and the forfeiture rate will be adjusted as necessary. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected lives for options granted represents the period of time that options granted are expected to be outstanding. Since January 1, 2006, we have used the simplified method for determining the expected lives of options.

For awards with graded vesting, we allocate compensation costs under SFAS No. 123R on a straight-line basis over the requisite service period. Accordingly, we amortized the fair value of each option over each option’s service period, which is generally the vesting period.

We account for stock options issued to non-employees in accordance with the provisions of of Statement of Financial Accounting Standards, or SFAS, No. 123, Accounting for Stock-Based Compensation, or SFAS 123, and Emerging Issues Task Force, or EITF, No. 96-18, Accounting for Equity Instruments that are Issued to Other than Employees, or in Conjunction with Selling Goods or Services, which requires valuing and remeasuring such stock options to the current fair value until the performance date has been reached.

Our net loss for the three months and six months ended June 30, 2007 and 2006 includes $1.5 million, $1.3 million, $2.9 million and $2.3 million, respectively, of compensation costs and no income tax benefit related to our stock-based compensation arrangements for employee and non-employee awards. As of June 30, 2007, the total amount of unrecognized stock-based compensation expense is $15.9 million and will be recognized over a weighted average period of 4.5 years.

Consolidated Results of Operations

Three Months Ended June 30, 2007 Compared with Three Months Ended June 30, 2006

Revenue. There were no revenues for the three months ended June 30, 2007 and 2006.

Research and development. Research and development expense increased to $13.6 million in the three months ended June 30, 2007 from $13.1 million in the three months ended June 30, 2006. This increase principally resulted from an increase of $0.7 million for personnel costs, related research supplies and operational overhead, and an increase in stock-based compensation expense of $0.1 million, offset by a net decrease of $0.3 million in external costs in clinical trials, animal studies and other preclinical testing, clinical product manufacturing, and consulting. In the three months ended June 30, 2007, external costs incurred under the STA-4783 program increased by $3.2 million over the same period in 2006, principally due to start-up expenses incurred in connection with the Phase 3 clinical trial of STA-4783 for the treatment of metastatic melanoma, which is targeted to commence in the third quarter of 2007. In the three months ended June 30, 2007, external costs incurred in connection with apilimod for the treatment of Crohn’s disease decreased by $2.6 million over the same period in 2006, as the Phase 2b clinical trial was terminated in June 2006. In addition, external costs incurred in the three months ended June 30, 2007 in connection with STA-9090 decreased by $0.7 million over the same period in 2006, as pre-clinical development efforts of STA-9090 were completing in advance of a planned filing of an IND in the third quarter of 2007.

General and administrative. General and administrative expense increased to $3.9 million in the three months ended June 30, 2007 from $1.9 million in the three months ended June 30, 2006. This increase was due to an increase of $0.6 million for personnel costs and related overhead in connection with increased headcount and an increase of $1.2 million in external professional fees, including investor and medical community relations, public-company reporting requirements, intellectual property and general legal fees, and increased directors and officers insurance premiums.

Investment income, net. Net investment income increased to $0.7 million in the three months ended June 30, 2007 from $0.3 million in the three months ended June 30, 2006. The increase in investment income was principally due to the higher average investment balance resulting from net cash proceeds of $44.7 million raised from the sale of our common stock in the IPO.

Net loss. Net loss for the three months ended June 30, 2007 increased to $16.7 million from $14.6 million for the three months ended June 30, 2006. Basic and diluted net loss per share attributable to common stockholders decreased to $0.50 for the three months ended June 30, 2007 from $0.67 for the three months ended June 30, 2006 principally due to an increase in the number of weighted average common shares outstanding resulting from the sale of 5,000,000 shares of common stock and the conversion of the Series A preferred stock into 6,278,765 shares of common stock in connection with the IPO.

Six Months Ended June 30, 2007 Compared with Six Months Ended June 30, 2006

Revenue. There were no revenues for the six months ended June 30, 2007 and 2006.

Research and development. Research and development expense decreased to $27.2 million in the six months ended June 30, 2007 from $27.5 million in the six months ended June 30, 2006. This decrease principally resulted from a net decrease of $1.8 million in external costs in clinical trials, animal studies and other preclinical testing, clinical product manufacturing, and consulting, offset by an increase of $1.0 million for personnel costs, related research supplies and operational overhead, and an increase in stock-based compensation expense of $0.5 million. In the six months ended June 30, 2007, external costs incurred under the STA-4783 program increased by $5.1 million over the same period in 2006, principally due to start-up expenses incurred in connection with the Phase 3 clinical trial of STA-4783 for the

treatment of metastatic melanoma, which is targeted to commence in the third quarter of 2007. In the six months ended June 30, 2007, external costs incurred in connection with apilimod for the treatment of Crohn’s disease decreased by $5.7 million over the same period in 2006, as the Phase 2b clinical trial was terminated in June 2006. In addition, external costs incurred in the six months ended June 30, 2007 in connection with STA-9090 decreased by $0.4 million over the same period in 2006, as pre-clinical development efforts of STA-9090 were completing in advance of a planned filing of an IND in the third quarter of 2007.

General and administrative. General and administrative expense increased to $7.3 million in the six months ended June 30, 2007 from $4.1 million in the six months ended June 30, 2006. This increase was due to an increase of $1.3 million for personnel costs and related overhead in connection with increased headcount and an increase of $1.9 million in external professional fees, including investor and medical community relations, public-company reporting requirements, intellectual property and general legal fees, and increased directors and officers insurance premiums.

Investment income, net. Net investment income increased to $1.4 million in the six months ended June 30, 2007 from $0.7 million in the six months ended June 30, 2006. The increase in investment income was principally due to the higher average investment balance resulting from net cash proceeds of $44.7 million raised from the sale of our common stock in the IPO.

Net loss. Net loss for the six months ended June 30, 2007 increased to $33.1 million from $30.9 million for the six months ended June 30, 2006. Basic and diluted net loss per share attributable to common stockholders increased to $2.96 for the six months ended June 30, 2007 from $1.40 for the six months ended June 30, 2006. The increase was principally due to the non-cash beneficial conversion charge of approximately $58.6 million that was recognized in February 2007 in connection with the contingent adjustable conversion feature of the Series A convertible preferred stock that converted into common stock upon the completion of the IPO in February 2007, offset in part by an increase in the number of weighted average common shares outstanding resulting from the sale of 5,000,000 shares of common stock and the conversion of the Series A preferred stock into 6,278,765 shares of common stock in connection with the IPO.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred significant operating losses since our inception. We have funded our operations principally with $195.4 million in net proceeds from private placements of our common stock, $40.0 million in net proceeds from a private placement of our Series A convertible preferred stock and $44.7 million in net proceeds from the IPO, which, together with the exercise of common stock warrants and options, provided aggregate net cash proceeds of approximately $281.3 million through June 30, 2007. We have also generated funds from government grant revenues, equipment lease financings and investment income.

As of June 30, 2007, we had cash, cash equivalents and marketable securities of $64.5 million, an increase of $17.7 million from $46.8 million as of December 31, 2006. This increase principally reflects $44.7 million of net proceeds from our IPO, less our net loss of $33.1 million during the six months ended June 30, 2007. Our funds are currently invested in money-market funds.

Under our equipment lease agreement, we may periodically directly lease, or sell and lease back up to a maximum outstanding balance of $6.0 million of equipment and leasehold improvements. In June 2007, this agreement was extended through May 31, 2008. As of June 30, 2007, approximately $1.0 million was available under this revolving lease line for future property and equipment expenditures.

Cash Flows

The following table provides information regarding our cash flows and our capital expenditures for the six months ended June 30, 2007 and 2006 (in thousands).

	2007			2006
Cash provided by (used in):
Operating activities	$	(25,745	)	$	(30,092	)
Investing activities	12,311			37,647
Financing activities	44,273			39,859
Capital expenditures (included in investing activities above)	(824		)	(642		)

Our operating activities used cash of $25.7 million and $30.1 million in the six months ended June 30, 2007 and 2006, respectively. The use of cash in these periods principally resulted from our losses from operations, adjusted for non-cash charges for depreciation and stock-based compensation, and changes in our working capital accounts.

Our investing activities provided cash of $12.3 million and $37.6 million in the six months ended June 30, 2007 and 2006, respectively. Our investing activities in the six months ended June 30, 2007 included sales and maturities of marketable securities in our investment portfolio in the amount of $28.1 million, offset by the purchases of marketable securities in the amount of $15.0 million and purchases of property and equipment in the amount of $0.8 million. Our investing activities in the six months ended June 30, 2006 included sales and maturities of marketable securities in our investment portfolio in the amount of $72.6 million, offset by the purchases of marketable securities in the amount of $34.3 million and purchases of property and equipment in the amount of $0.6 million.

Our financing activities provided $44.3 million and $39.9 million in the six months ended June 30, 2007 and 2006, respectively. In February 2007, we raised net cash proceeds of $44.7 million from the sale of 5,000,000 shares of common stock in the IPO. In June 2006, we raised gross proceeds of $40.0 million from the sale of 8,000,000 shares of our Series A convertible preferred stock. We raised $1.2 million and $0.9 million in proceeds from the sale and lease-back of property and equipment in the six months ended June 30, 2007 and 2006, respectively. We repaid $1.3 million and $1.0 million in capital equipment leases in the six months ended June 30, 2007 and 2006, respectively. In January 2007, we repurchased 29,046 shares of our previously restricted common stock in the amount of $0.3 million from certain officers and non-officer employees in order to fund the minimum statutory tax withholding requirements related to the vesting of 80,000 shares of restricted common stock.

Contractual Obligations and Commitments

There have been no material changes to the contractual obligations and commitments included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

Funding Requirements

We expect to incur substantial expenses and generate significant operating losses as we continue to advance our drug candidates into preclinical studies and clinical trials and as we:

· initiate a pivotal Phase 3 clinical trial of STA-4783 for the treatment of metastatic melanoma in the third quarter of 2007 and announce plans to initiate a Phase 2 clinical trial of STA-4783 in one additional cancer indication by the end of 2007;

· begin to establish sales and marketing functions and commercial manufacturing arrangements for STA-4783;

· complete the current Phase 2a clinical trials of apilimod for the treatment of rheumatoid arthritis and CVID, and possibly initiate Phase 2 clinical trials of apilimod in additional inflammatory disease indications;

· initiate additional Phase 3 clinical trials of STA-4783 in additional cancer indications and one or more Phase 3 clinical trials of apilimod, if supported by Phase 2 results;

· complete preclinical development of STA-9090 and initiate a Phase 1 clinical trial in 2007;

· complete preclinical development of STA-9584 and initiate clinical trials, if supported by positive preclinical data;

· advance our CRAC ion channel inhibitor program into clinical trials, if supported by positive preclinical data;

· discover, develop, and seek regulatory approval for backups of our current drug candidates and other new drug candidates;

· identify additional compounds or drug candidates and acquire rights from third parties to those compounds or drug candidates through licenses, acquisition or other means;

· commercialize any approved drug candidates;

· hire additional clinical, scientific, and management personnel; and

· add operational, financial, and management information systems and personnel.

Our funding requirements will depend on a number of factors, including:

· the progress of our research and development programs, including the completion of preclinical and clinical trials for our current drug candidates and the results from these studies and trials;

· the number of drug candidates we advance into later-stage clinical trials and the scope of our research and development programs;

· our ability to discover additional drug candidates using our drug discovery technology and advance them into clinical development;

· the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims for our drug discovery technology and drug candidates and avoiding infringing the intellectual property of others;

· the time and costs involved in obtaining regulatory approvals for our drug candidates;

· our ability to establish and maintain collaborative arrangements;

· the potential in-licensing of other products or technologies or the acquisition of complementary businesses;

· the cost of manufacturing, marketing and sales activities, if any; and

· the timing, receipt and amount of revenue, if any, from our drug candidates.

We do not anticipate that we will generate product revenue for the next several years. We expect our continuing operating losses to result in increases in cash used in operations over the next several years. Our future capital requirements will depend on a number of factors including the progress and results of our clinical trials, the costs, timing and outcome of regulatory review of our drug candidates, our revenue, if any, from successful development and commercialization of our products, the costs of commercialization activities, the scope, progress, results and costs of preclinical development, laboratory testing and clinical

trials for other drug candidates, the emergence of competing therapies and other market developments, the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property rights, the extent to which we acquire or invest in other drugs and technologies, and our ability to establish collaborations and obtain milestone, royalty or other payments from any collaborators.

Based on our current operating plans, we expect our existing funds will be sufficient to fund our operations through at least mid-2008. However, we may require significant additional funds earlier than we currently expect to conduct additional clinical trials and seek regulatory approval of our drug candidates. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders may result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay our research and development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or drug candidates that we might otherwise seek to develop or commercialize independently. We may elect to raise additional funds even before we need them if the conditions for raising capital are favorable.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or relationships with unconsolidated entities of financial partnerships, such as entities often referred to as structured finance or special purpose entities.

Recently Issued Accounting Pronouncements

In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FAS 109, or Interpretation No. 48. This interpretation clarifies the accounting for uncertainty in income taxes recognized in a company’s financial statements in accordance with FASB Statement No. 109, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken in a tax return. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Interpretation No. 48 is effective for fiscal years beginning after December 15, 2006. We adopted Interpretation No. 48 effective January 1, 2007 and its adoption had no impact on our consolidated results of operations and financial position.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, or SFAS No. 157, which provides guidance for using fair value to measure assets and liabilities. The pronouncement clarifies (1) the extent to which companies measure assets and liabilities at fair value; (2) the information used to measure fair value; and (3) the effect that fair value measurements have on earnings. SFAS No. 157 will apply whenever another standard requires (or permits) assets or liabilities to be measured at fair value. SFAS No. 157 will be applicable to us as of January 1, 2008. We do not believe the adoption of SFAS No. 157 will have a material impact on our overall financial position or results of operations.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities or SFAS No. 159, including an amendment of SFAS No. 115, which permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 is effective for us beginning in fiscal 2008. We are currently evaluating SFAS No. 159 and the impact that it may have on our results of operations or financial position.

In June 2007, the EITF issued EITF No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, (EITF 7-03), which provides guidance for upfront payments related to goods and services of research and development costs. EITF 07-03 is effective for fiscal years beginning after December 15, 2007. We are currently evaluating EITF 7-03 and the impact that it may have on our results of operations or financial position.

Certain Factors That May Affect Future Results of Operations

The Securities and Exchange Commission, or SEC, encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to those set forth under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2006 that we have filed with the SEC.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to Synta or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. As of June 30, 2007, we had cash, cash equivalents and marketable securities of $64.5 million consisting of cash and highly liquid, short-term investments. Our cash is deposited in and invested through highly rated financial institutions in North America. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. If market interest rates were to increase immediately and uniformly by 10% from levels at June 30, 2007, we estimate that the fair value of our investments will decline by an immaterial amount, and therefore, our exposure to interest rate changes is not significant.

Item 4T. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were adequate and effective. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

We are currently not a party to any material legal proceedings.

Item 1A. Risk Factors.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Unregistered Sales of Equity Securities.

None.

(b) Use of Proceeds.

The Registration Statement on Form S-1 (Reg. No. 333-138894) in connection with our initial public offering was declared effective by the SEC on February 6, 2007. In the initial public offering, we sold 5,000,000 shares of our common stock at an initial public offering price per share of $10.00. The net offering proceeds to us after deducting total expenses were approximately $44,700,000. As of June 30, 2007, approximately $21.8 million of the net proceeds of the offering had been used to fund operations. The remaining net proceeds have been invested in money market accounts. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus dated February 6, 2007 filed with the SEC pursuant to Rule 424(b)(4).

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

(a) Exhibits

31.1		Certification of principal executive officer under Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2		Certification of principal financial officer under Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1		Certifications of the principal executive officer and the principal financial officer under Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.
Date: August 6, 2007	By:	/s/ SAFI R. BAHCALL
		Safi R. Bahcall, Ph.D.
		President and Chief Executive Officer
		(principal executive officer)
Date: August 6, 2007	By:	/s/ KEITH S. EHRLICH
		Keith S. Ehrlich, C.P.A.
		Vice President Finance and Administration,
		Chief Financial Officer (principal
		accounting and financial officer)